Therapeutic effect of recombinant human erythropoietin on anaemia with erythropoietin deficiency in diabetic patients

D. J. Kim, Y. M. Kim, Y. S. Yun, C. W. Ahn, B. S. Cha, Y. D. Song, S. K. Lim, K. R. Kim, J. S. Hahnt, K. B. Huh, Hyun Chul Lee

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aims: The aim of this study was to investigate the therapeutic effect of recombinant human erythropoietin (rHuEpo) on anaemia with erythropoietin deficiency in diabetic patients. Methods: Twenty diabetic patients with anaemia and Epo deficiency were enrolled. All patients were treated with rHuEpo (Epokine®; 4000 U/day s.c., three times a week) for 8 weeks. Results: The responder group (n = 14) had significant increments in haemoglobin compared with the non-responder group (n = 6) (P < 0.05). No significant differences were found between the responder and non-responder groups in terms of duration of diabetes mellitus, serum creatinine level, 24-h urine albumin excretion rates, frequency of diabetic microangiopathy, or HbA1c. There was no difference between the two groups in terms of serum iron and total iron-binding capacity (TIBC). Serum ferritin level was significantly higher in the responder group than in the non-responder group (240.3 ± 108.4, 25.8 ± 3.0 μg/1, P < 0.05), as was transferrin saturation (32.7 ± 7.9%, 21.2 ± 5.3%, P < 0.05). Conclusions: rHuEpo could be useful in the treatment of anaemia with erythropoietin deficiency in diabetic patients, and the degree of iron storage and functional iron deficiency might be the main cause of hyporesponsiveness to rHuEpo.

Original languageEnglish
Pages (from-to)661-664
Number of pages4
JournalDiabetic Medicine
Volume20
Issue number8
DOIs
Publication statusPublished - 2003 Aug 1

Fingerprint

Therapeutic Uses
Erythropoietin
Anemia
Iron
Serum
Diabetic Angiopathies
Transferrin
Ferritins
Albumins
Creatinine
Diabetes Mellitus
Hemoglobins
Urine

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Kim, D. J. ; Kim, Y. M. ; Yun, Y. S. ; Ahn, C. W. ; Cha, B. S. ; Song, Y. D. ; Lim, S. K. ; Kim, K. R. ; Hahnt, J. S. ; Huh, K. B. ; Lee, Hyun Chul. / Therapeutic effect of recombinant human erythropoietin on anaemia with erythropoietin deficiency in diabetic patients. In: Diabetic Medicine. 2003 ; Vol. 20, No. 8. pp. 661-664.
@article{57571d5663244ef1950e0790b49cfa9a,
title = "Therapeutic effect of recombinant human erythropoietin on anaemia with erythropoietin deficiency in diabetic patients",
abstract = "Aims: The aim of this study was to investigate the therapeutic effect of recombinant human erythropoietin (rHuEpo) on anaemia with erythropoietin deficiency in diabetic patients. Methods: Twenty diabetic patients with anaemia and Epo deficiency were enrolled. All patients were treated with rHuEpo (Epokine{\circledR}; 4000 U/day s.c., three times a week) for 8 weeks. Results: The responder group (n = 14) had significant increments in haemoglobin compared with the non-responder group (n = 6) (P < 0.05). No significant differences were found between the responder and non-responder groups in terms of duration of diabetes mellitus, serum creatinine level, 24-h urine albumin excretion rates, frequency of diabetic microangiopathy, or HbA1c. There was no difference between the two groups in terms of serum iron and total iron-binding capacity (TIBC). Serum ferritin level was significantly higher in the responder group than in the non-responder group (240.3 ± 108.4, 25.8 ± 3.0 μg/1, P < 0.05), as was transferrin saturation (32.7 ± 7.9{\%}, 21.2 ± 5.3{\%}, P < 0.05). Conclusions: rHuEpo could be useful in the treatment of anaemia with erythropoietin deficiency in diabetic patients, and the degree of iron storage and functional iron deficiency might be the main cause of hyporesponsiveness to rHuEpo.",
author = "Kim, {D. J.} and Kim, {Y. M.} and Yun, {Y. S.} and Ahn, {C. W.} and Cha, {B. S.} and Song, {Y. D.} and Lim, {S. K.} and Kim, {K. R.} and Hahnt, {J. S.} and Huh, {K. B.} and Lee, {Hyun Chul}",
year = "2003",
month = "8",
day = "1",
doi = "10.1046/j.1464-5491.2003.01012.x",
language = "English",
volume = "20",
pages = "661--664",
journal = "Diabetic Medicine",
issn = "0742-3071",
publisher = "Wiley-Blackwell",
number = "8",

}

Kim, DJ, Kim, YM, Yun, YS, Ahn, CW, Cha, BS, Song, YD, Lim, SK, Kim, KR, Hahnt, JS, Huh, KB & Lee, HC 2003, 'Therapeutic effect of recombinant human erythropoietin on anaemia with erythropoietin deficiency in diabetic patients', Diabetic Medicine, vol. 20, no. 8, pp. 661-664. https://doi.org/10.1046/j.1464-5491.2003.01012.x

Therapeutic effect of recombinant human erythropoietin on anaemia with erythropoietin deficiency in diabetic patients. / Kim, D. J.; Kim, Y. M.; Yun, Y. S.; Ahn, C. W.; Cha, B. S.; Song, Y. D.; Lim, S. K.; Kim, K. R.; Hahnt, J. S.; Huh, K. B.; Lee, Hyun Chul.

In: Diabetic Medicine, Vol. 20, No. 8, 01.08.2003, p. 661-664.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Therapeutic effect of recombinant human erythropoietin on anaemia with erythropoietin deficiency in diabetic patients

AU - Kim, D. J.

AU - Kim, Y. M.

AU - Yun, Y. S.

AU - Ahn, C. W.

AU - Cha, B. S.

AU - Song, Y. D.

AU - Lim, S. K.

AU - Kim, K. R.

AU - Hahnt, J. S.

AU - Huh, K. B.

AU - Lee, Hyun Chul

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Aims: The aim of this study was to investigate the therapeutic effect of recombinant human erythropoietin (rHuEpo) on anaemia with erythropoietin deficiency in diabetic patients. Methods: Twenty diabetic patients with anaemia and Epo deficiency were enrolled. All patients were treated with rHuEpo (Epokine®; 4000 U/day s.c., three times a week) for 8 weeks. Results: The responder group (n = 14) had significant increments in haemoglobin compared with the non-responder group (n = 6) (P < 0.05). No significant differences were found between the responder and non-responder groups in terms of duration of diabetes mellitus, serum creatinine level, 24-h urine albumin excretion rates, frequency of diabetic microangiopathy, or HbA1c. There was no difference between the two groups in terms of serum iron and total iron-binding capacity (TIBC). Serum ferritin level was significantly higher in the responder group than in the non-responder group (240.3 ± 108.4, 25.8 ± 3.0 μg/1, P < 0.05), as was transferrin saturation (32.7 ± 7.9%, 21.2 ± 5.3%, P < 0.05). Conclusions: rHuEpo could be useful in the treatment of anaemia with erythropoietin deficiency in diabetic patients, and the degree of iron storage and functional iron deficiency might be the main cause of hyporesponsiveness to rHuEpo.

AB - Aims: The aim of this study was to investigate the therapeutic effect of recombinant human erythropoietin (rHuEpo) on anaemia with erythropoietin deficiency in diabetic patients. Methods: Twenty diabetic patients with anaemia and Epo deficiency were enrolled. All patients were treated with rHuEpo (Epokine®; 4000 U/day s.c., three times a week) for 8 weeks. Results: The responder group (n = 14) had significant increments in haemoglobin compared with the non-responder group (n = 6) (P < 0.05). No significant differences were found between the responder and non-responder groups in terms of duration of diabetes mellitus, serum creatinine level, 24-h urine albumin excretion rates, frequency of diabetic microangiopathy, or HbA1c. There was no difference between the two groups in terms of serum iron and total iron-binding capacity (TIBC). Serum ferritin level was significantly higher in the responder group than in the non-responder group (240.3 ± 108.4, 25.8 ± 3.0 μg/1, P < 0.05), as was transferrin saturation (32.7 ± 7.9%, 21.2 ± 5.3%, P < 0.05). Conclusions: rHuEpo could be useful in the treatment of anaemia with erythropoietin deficiency in diabetic patients, and the degree of iron storage and functional iron deficiency might be the main cause of hyporesponsiveness to rHuEpo.

UR - http://www.scopus.com/inward/record.url?scp=0042134554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042134554&partnerID=8YFLogxK

U2 - 10.1046/j.1464-5491.2003.01012.x

DO - 10.1046/j.1464-5491.2003.01012.x

M3 - Article

C2 - 12873295

AN - SCOPUS:0042134554

VL - 20

SP - 661

EP - 664

JO - Diabetic Medicine

JF - Diabetic Medicine

SN - 0742-3071

IS - 8

ER -